竞争型医药供应链研发创新策略及行为选择  

R&D innovation strategy and behavior choice of competition drug supply chain

作　　者：温艳[1] 于溪源 胡劲松[1] WEN Yan;YU Xiyuan;HU Jinsong(School of Business,Qingdao University,Qingdao 266071,Shandong,China)

机构地区：[1]青岛大学商学院,山东青岛266071

出　　处：《山东大学学报（理学版）》2023年第7期18-31,共14页Journal of Shandong University(Natural Science)

基　　金：国家自然科学基金资助项目(71771129);山东省自然科学基金资助项目(ZR2019MG001);青岛市博士后应用研究项目(40518060048)。

摘　　要：针对竞争型医药供应链成员的短视与远见行为构建了4种动态微分博弈模型,研究不同行为选择、竞争强度变动、医保报销比例对药品制造商研发创新投入、医疗机构成本分担策略及供应链绩效的影响。研究发现,医药企业间的竞争性虽然损害了短视制造商的利润,但增加了医药供应链整体绩效,同时更有助于促进远见制造商更高的研发创新投入。伴随医保报销比例的提高,远见药品制造商及医疗机构的利润均增加,但无益于短视药品制造商。此外,医疗机构为其中一制造商分担成本,会抑制另一制造商利润的增长,只有选择同时为两竞争制造商分担药品研发创新成本行为模式时,才能对医药供应链各成员利润均有利。Based on the short-sighted and far-sighted behaviors of members of competitive drug supply chain,four dynamic differential game models were constructed to study the influences of different behavior choices,changes in competition intensity and reimbursement ratio of medical insurance on drug manufacturersR&D innovation investment,medical institutioncost-sharing strategies and supply chain performance.The study found that although the competition between drug manufacturers harms the profits of short-sighted manufacturer,it increases the overall performance of the drug supply chain and promotes the higher R&D innovation investment of far-sighted manufacturer.With higher reimbursement rate,both far-sighted drug manufacturer and medical institution have increased their profits,but not short-sighted drug manufacturer.In addition,medical institution sharing costs with one manufacturer would depress the profits of the other,when medical institution choose the behavior mode of sharing drug R&D innovation costs for two competing manufacturers simultaneously,they can benefit the profits of all members of the drug supply chain.

关 键 词：短视与远见 成本分担 微分博弈 医药供应链 竞争制造商 

分 类 号：F224[经济管理—国民经济]